DOI: http://dx.doi.org/10.18203/2349-3933.ijam20201129

A review of relationship between platelet indices and microvascular complications in type 2 diabetic patients

Subashini Subramanian, Siva Ranganathan Green

Abstract


Diabetes is a common metabolic disorder affecting the world population which accounts for major amount of morbidity and mortality mainly due to its micro vascular and macro vascular complications. This is a comparative study which analyses the correlation between the Platelet indices like Mean platelet volume, platelet distribution width, plateletcrit and total platelet count in diabetic patients with micro vascular complications and without complications. This review of the literature was conducted through an Internet search on a public access website like PubMed Google scholar, Medline databases until 2019. Keywords utilized included Diabetes mellitus, Microvascular complications, platelet indices. The major exclusion criteria was studies which included the patients with macrovascular complications and patients taking drugs which alters the platelet indices. All these articles were analysed. Platelet indices like Mean platelet volume and platelet distribution width was significantly higher in individuals with microvascular complications, predominantly Diabetic Nephropathy and Diabetic Retinopathy when compared to those without microvascular complications. Change in platelet indices were found to be statistically associated with diabetic microvascular complications. Hence these parameters can be used to monitor and to predict the risk of microvascular complications.


Keywords


Diabetes, Microangiopathy, Nephropathy, Neuropathy, Platelet indices, Retinopathy

Full Text:

PDF

References


Ramanathan RS. correlation of duration hypertension and glycemic control with microvascular complications of diabetes mellitus at a tertiary care hospital. J Neurol Experimen Neural Sci. 2017 Feb 14.

Saydah S, Lochner K. Socioeconomic Status and Risk of Diabetes-Related Mortality in the U.S. Public Health Rep. 2010 May 1;125(3):377-88.

Bertoni AG, Krop JS, Anderson GF, Brancati FL. Diabetes-Related Morbidity and Mortality in a National Sample of U.S. Elders. Diab Care. 2002 Mar 1;25(3):471-5.

Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of Diabetes and Diabetes-Related Complications. Physical Ther. 2008 Nov 1;88(11):1254-64.

Ciulla TA, Amador AG, Zinman B. Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies. Diab Care. 2003 Sep 1;26(9):2653-64.

Bursell SE, Cavallerano JD, Cavallerano AA, Clermont AC, Birkmire-Peters D, Aiello LP, et al. Stereo nonmydriatic digital-video color retinal imaging compared with Early Treatment Diabetic Retinopathy Study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy. Ophthalmol. 2001;108(3):572-85.

Hutchinson A, McIntosh A, Peters J, O’keeffe C, Khunti K, Baker R, et al. Effectiveness of screening and monitoring tests for diabetic retinopathy – a systematic review. Diab Med. 2000;17(7):495-506.

Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmol. 2003 Sep 1;110(9):1677-82.

Treatment Techniques and Clinical Guidelines for Photocoagulation of Diabetic Macular Edema: Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmol. 1987 Jul 1;94(7):761-74.

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31.

Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010 Jul 1;248(7):915-30.

Group1A VI. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001 May 1;131(5):541-60.

Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Inter. 2003;63(1):225-32.

Misra A, Tandon N, Ebrahim S, Sattar N, Alam D, Shrivastava U, et al. Diabetes, cardiovascular disease, and chronic kidney disease in South Asia: current status and future directions. BMJ. 2017 Apr 11;357:j1420.

Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Europ J Clini Investig. 2004 Dec 1;34(12):785-96.

Cooper ME, Gilbert RE, Epstein M. Pathophysiology of diabetic nephropathy. Metab. 1998 Dec;47:3-6.

Mogensen CE, Christensen CK, Vittinghus E. The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy. Diab. 1983 Jun 1;32(Supplement 2):64-78.

Raparia K, Usman I, Kanwar YS. Renal Morphologic Lesions Reminiscent of Diabetic Nephropathy. Arch Pathol Lab Med. 2013 Mar;137(3):351-9.

Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diab Care. 2005 Jan 1;28(1):164-76.

Pradeepa R, Rema M, Vignesh J, Deepa M, Deepa R, Mohan V. Prevalence and risk factors for diabetic neuropathy in an urban south Indian population: the Chennai Urban Rural Epidemiology Study (CURES-55). Diab Med. 2008;25(4):407-12.

Ashok S, Ramu M, Deepa R, Mohan V. Prevalence of Neuropathy in Type 2 Diabetic Patients Attending a Diabetes Centre in South India. JAPI. 2002 Apr 1;50:546-50.

Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diab Care. 2010 Oct 1;33(10):2285-93.

Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diab Metab Rev. 1995 Oct;11(3):193-225.

Negi G, Kumar A, Joshi RP, Sharma SS. Oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: Old perspective with a new angle. Biochem Biophysi Res Communic. 2011 Apr;408(1):1-5.

Giovanetti TV, do Nascimento AJ, de Paula JP. Platelet indices: laboratory and clinical applications. Rev Bras Hematol Hemoter. 2011;33(2):164–5.

Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet Dysfunction in Type 2 Diabetes. Diab Care. 2001 Aug 1;24(8):1476-85.

Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, et al. Thromboxane Biosynthesis and Platelet Function in Type II Diabetes Mellitus. N Engl J Med. 1990 Jun 21;322(25):1769-74.

Hekimsoy Z, Payzin B, Örnek T, Kandoğan G. Mean platelet volume in Type 2 diabetic patients. J Diab Complicat. 2004 May 1;18(3):173-6.

Buch A, Kaur S, Nair R, Jain A. Platelet volume indices as predictive biomarkers for diabetic complications in Type 2 diabetic patients. J Lab Physicians. 2017;9(2):84-8.

Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thrombosis Haemostasis. 2010;8(1):148–56.

Walinjkar RS, Khadse S, Kumar S, Bawankule S, Acharya S. Platelet Indices as a Predictor of Microvascular Complications in Type 2 Diabetes. Ind J Endocrinol Metab. 2019 Mar 1;23(2):206.

Yilmaz T, Yilmaz A. Relationship between Altered Platelet Morphological Parameters and Retinopathy in Patients with Type 2 Diabetes Mellitus. J Ophthalmol. 2016;2016:1-5.

Citirik M, Beyazyildiz E, Simsek M, Beyazyildiz O, Haznedaroglu IC. MPV may reflect subcinical platelet activation in diabetic patients with and without diabetic retinopathy. Eye. 2015 Mar;29(3):376-9.

Ünübol M, Ayhan M, Güney E. The relationship between mean platelet volume with microalbuminuria and glycemic control in patients with type II diabetes mellitus. Platelets. 2012;23(6):475-80.

Chen X, Fang L, Lin H, Shen P, Zhang T, LI H, et al. The Relationship between Type 2 Diabetes and Platelet Indicators. Iran J Public Health. 2017 Sep;46(9):1211-6.

Jindal S, Gupta S, Gupta R, Kakkar A, Singh HV, Gupta K, et al. Platelet indices in diabetes mellitus: indicators of diabetic microvascular complications. Hematol. 2011 Mar;16(2):86-9.

Shilpi K, Potekar RM. A Study of Platelet Indices in Type 2 Diabetes Mellitus Patients. Indian J Hematol Blood Transfus. 2018 Jan;34(1):115-20.

Sushma KL, Rangaswamy M. Study of Platelet Indices in Type 2 Diabetic Patients and Its Correlation With Vascular Complications. Ann Pathol Lab Med. 2017 Oct 30;4(5):A591-8.

Schwarz RE. Platelet counts and prognosis of pancreatic cancer. Lancet. 1999 Jun 19;353(9170):2158-9.

Ateş O, Kiki I, Bilen H, Keleş M, Koçer İ, Kulaçoğlu DN, et al. Association of mean platelet volume with the degree of retinopathy in patients with diabetes mellitus. Eur J Gen Med. 2009 Jun 1;6(2):99-102.

Martyn CN, Matthews DM, Popp-Snijders C, Tucker J, Ewing DJ, Clarke BF. Effects of Sorbinil Treatment on Erythrocytes and Platelets of Persons with Diabetes. Diab Care. 1986 Jan 1;9(1):36-9.

Dalamaga M, Karmaniolas K, Lekka A, Antonakos G, Thrasyvoulides A, Papadavid E, et al. Platelet markers correlate with glycemic indices in diabetic, but not diabetic-myelodysplastic patients with normal platelet count. Dis Markers. 2010;29(1):55-61.

Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, Labrianou I. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia. 2010 Jan;14(1):28-32.